Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir

American Journal on Addictions

Volumn 16, Issue 6, 2007, Pages 488-494

  Higgins, Niamh ^a   Zingman, Barry S ^b   Slish, Judianne ^a   Reichman, Richard C ^c   Fischl, Margaret A ^d   Gripshover, Barbara ^e   Tooley, Kelly ^a   Boston, Naomi ^a   Forrest, Alan ^a   Brazeau, Dan ^a   Catanzaro, Linda M ^a   DiFrancesco, Robin ^a   Lliguicota, Francesco ^a   Ma, Qing ^a   Morse, Gene D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; RITONAVIR;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SELF MEDICATION; SUBSTANCE ABUSE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; METHADONE; MIDDLE AGED; OLIGOPEPTIDES; PATIENT COMPLIANCE; PYRIDINES; PYRIMIDINONES; SMOKING; SUBSTANCE-RELATED DISORDERS;

EID: 33947601056     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490701641256     Document Type: Article

References (41)

1. Beyrer C. HIV epidemiology update and transmission factors: risks and risk contexts. 16th International AIDS Conference Epidemiology Plenary. Clin Infect Dis. 2007;44:981-987.
2. Chawarski MC, Mazlan M, Schottenfeld RS. Heroin dependence and HIV infection in Malaysia. Drug Alcohol Depend. 2006;82 (Suppl. 1):S39-S42.
3. Surratt HL, Inciardi JA, Weaver JC, Falu VM. Emerging linkages between substance abuse and HIV infection in St. Croix, US Virgin Islands. AIDS Care. 2005;17 (Suppl. 1):S26-S35.
4. Kapadia F, Vlahov D, Donahoe RM, Friedland G. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis. 2005;41:1027-1034.
5. Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction. 2005;100:150-158.
6. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642-654.
7. Beckson M, Schaefer M. Assessment of HIV risk outcomes in clinical trials for substance abuse pharmacology. NIDA Res Monogr. 1996;162:46-48.
8. Francis H. Substance abuse and HIV infection. Top HIV Med. 2003;11:20-24.
9. Royce RA, Sena A, Cates W, Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med. 1997;336:1072-1078.
10. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999;13:1099-1107.
11. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-381.
12. Arici C, Ripamonti D, Maggiolo F, et al. Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials. 2002;3:52-57.
13. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573-580.
14. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386-395.
15. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
16. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
17. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:824-830.
18. Vlahov D, Galai N, Safaeian M, et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol. 2005;161:999-1012.
19. Wang C, Vlahov D, Galai N, et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis. 2004;190:1046-1054.
20. Wertheimer BZ, Freedberg KA, Walensky RP, Yazdanapah Y, Losina E. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin Trials. 2006;7:59-69.
21. Morse GD, Catanzaro LM, Acosta EP. Clinical pharmacodynamics of HIV-1 protease inhibitors: Use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect Dis. 2006;6:215-225.
22. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32:210-258.
23. Ray JE, Marriott D, Bloch MT, McLachlan AJ. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol. 2005;60:291-299.
24. Droste JA, Koopmans PP, Hekster YA, Burger DM. TDM: therapeutic drug measuring or therapeutic drug monitoring? Ther Drug Monit. 2005;27:412-416.
25. Boffito M, Acosta E, Burger D, et al. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther. 2005;10:469-477.
26. Molto J, Clotet B. Therapeutic drug monitoring of antiretroviral agents scenario. J HIV Ther. 2004;9:75-78.
27. Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, Kurowski M, Luber A, Merry C, Perno C. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002;16:S5-S37.
28. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003;17:1157-1165.
29. Burger DM, Grintjes KJ, Lotgering FK, Koopmans PP. Therapeutic drug monitoring of nelfinavir in pregnancy: a case report. Ther Drug Monit. 2004;26:576-578.
30. Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther. 1998;3:215-220.
31. Keil K, Frerichs VA, DiFrancesco R, Morse G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir, and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit. 2003;25:340-346.
32. Holland DT, DiFrancesco R, Connor JD, Morse GD. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit. 2006;28:367-374.
33. Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD. Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48:824-831.
34. Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. American Journal of Hospital Pharmacy. 1991;48:1978-1988.
35. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255-266.
36. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med. 2000;67:429-436.
37. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother. 2002;36:1598-1613.
38. Slish JC, Catanzaro LM, Ma Q, Okusanya OO, Demeter L, Albrecht M, Morse GD. Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring. Curr Pharm Des. 2006;12:1129-1145.
39. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999;36:425-438.
40. Gourevitch MN, Wasserman W, Panero MS, Selwyn PA. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis. 1996;15:93-104.
41. Risk behaviors for HIV transmission among intravenous-drug users not in drug treatment - United States, 1987-1989. MMWR Morb Mortal Wkly Rep. 1990;39:273-276.